Home > Business Cases > Reprofiling in Alzheimer
Reprofiling in Alzheimer
-
Public-private research consortium wants to conduct research in reprofiling in Alzheimer Disease.
-
Anaxomics builds the complete systems biology map of AD and related dementias.
-
Existing drugs are identified with a possible new MoA in AD.
-
The ones without any prior IP on CNS and which are able to cross BBB are selected for in vitro and in vivo experiments.
-
3 Drug combinations show promising results in in vitro and in vivo experiments by the MoA predicted by Anaxomics.
-
The 3 drug combinations are being fully validated in preclinical stage.
-
The 3 drug combinations are safe and generic for the previous known indications.
Academic Research Consortium decides to develop new therapies for Alzheimer's Disease by drug reprofiling.
Thanks to our technology we have identified 8 known compounds, without prior IP, with promising in vitro / in vivo results
Some of the combinations also show positive results in vitro / in vivo models
Reprofiling process
The use of Therapeutic Performance Mapping System© allows Anaxomics customers to find new potential cures for Alzheimer Disease.
The video below explains the System in more details:
Please, contact us here to request more information.
